Cataract Treatments

Find Cataract Treatments

Brand Name

Omidria

Generic Name

Ketorolac

View Brand Information

FDA approval date: June 13, 2014

Classification: alpha-1 Adrenergic Agonist

Form: Injection

What is Omidria (Ketorolac)?

Omidria ® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. OMIDRIA is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor indicated for: Maintaining pupil size by preventing intraoperative miosis Reducing postoperative pain OMIDRIA is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Safety of Short-term NSAID Use in the Postoperative Setting in Pediatric Patients With Chronic Kidney Disease

Enrollment Status: Recruiting

Publish Date: June 08, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: The purpose of this study is to determine if non-steroidal anti-inflammatory (NSAID) use in the postoperative setting increases the risk of acute kidney injury (AKI) in pediatric patients with mild-to-moderate chronic kidney disease (CKD). The investigators hypothesize that there is no increased risk. This is currently in the process of developing multi institution collaboration within a Pediatric...

Autonomic Control of the Circulation and the Venous Distension Reflex

Enrollment Status: Recruiting

Publish Date: June 02, 2026

Intervention Type: Other, Drug

Study Phase: Early Phase 1

Summary: The study objective of this project is to examine the mechanisms of the venous distension reflex (VDR) in humans. We hypothesize that COX blockade with ketorolac tromethamine, an intravenous NSAID, will attenuate the muscle sympathetic nerve activity (MSNA) response to limb venous distension. To gain further insight into whether the COX byproducts directly stimulate chemically-sensitive afferents,...

Intra-nasal Ketorolac Versus Oral Diclofenac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease

Enrollment Status: Recruiting

Publish Date: May 27, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Objective: To improve quality-of-life and health care delivery to patients receiving ureteral stents. Specific

View All Clinical Trials